INSTITUT CLAUDIUS REGAUD

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website: http://www.claudiusregaud.fr

Clinical Trials

Irradiation in Paediatrics: Neurocognition, Neuroimaging and Evaluation of Memory and Attention

Not Applicable

Not yet recruiting

Conditions: Brain Tumor, Pediatric

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-03

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 130

Registration Number: NCT06599879

Locations: 🇫🇷
CHU Angers, Angers, France
🇫🇷
CHU de Bordeaux, Bordeaux, France
🇫🇷
Centre François Baclesse, Caen, France

and more 13 locations

Reintegrating a Systematic Review Consultation With the General Practitioner After the Cancer Diagnosis Has Been Announced Into the Complex Cancer Patient Pathway: Feasibility Study

Not Applicable

Recruiting

Conditions: Solid Tumours

Interventions: Other: Patient care according to the DAMeGe protocol (organisation of a summary consultation with the GP)

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-03

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 171

Registration Number: NCT06589414

Locations: 🇫🇷
CH Auch, Auch, France
🇫🇷
CHU Larrey, Toulouse, France
🇫🇷
CHU Rangueil, Toulouse, France

and more 1 locations

Detection of Homologous Recombination Pathway Gene Mutations in Circulating Tumour DNA From BRCA-mutated Ovarian Cancer Patients Receiving First-line PARP Inhibitor Maintenance Therapy

Not Applicable

Recruiting

Conditions: Ovarian Cancer

First Posted Date: 2024-09-19

Last Posted Date: 2024-12-03

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 130

Registration Number: NCT06588322

Locations: 🇫🇷
INSTITUT DE CANCEROLOGIE DE L'OUEST - Site Angers, Angers, France
🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷
Chu de Limoges, Limoges, France

and more 3 locations

Reduction in the Number of Chemotherapy Cycles in Combination With Pembrolizumab in First-line Treatment of PD-L1-positive Recurrent or Metastatic Head and Neck Squamous Cell Carcinomas

Phase 2

Recruiting

Conditions: Squamous Cell Carcinoma of Head and Neck

Interventions: Drug: Pembrolizumab + Cisplatin/Carboplatin + 5-FU

First Posted Date: 2024-08-16

Last Posted Date: 2024-12-06

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 86

Registration Number: NCT06557889

Locations: 🇫🇷
Chu Bordeaux - Hopital Saint André, Bordeaux, France
🇫🇷
Chu Limoges, Limoges, France
🇫🇷
Centre Hospitalier Regional de Marseille, Marseille, France

and more 4 locations

Acceptability and Benefits of an Onco-sexology Program for Laryngectomy Patients and Their Partners

Recruiting

Conditions: ORL Cancer

First Posted Date: 2024-07-24

Last Posted Date: 2024-08-06

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 45

Registration Number: NCT06517355

Locations: 🇫🇷
IUCT-O, Toulouse, France

Are CK+/CD45+ Double-Positive Circulating Cells of Tumor-origin? Characterization in METAstatic Breast Cancer

Not Applicable

Recruiting

Conditions: Metastatic Breast Cancer

First Posted Date: 2024-05-09

Last Posted Date: 2024-07-10

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 60

Registration Number: NCT06408038

Locations: 🇫🇷
IUCT-O, Toulouse, France

Optimization With a Gamma Camera of the Individualized Patient Dosimetry in Radioiodine Therapy of Thyroid Diseases

Not Applicable

Recruiting

Conditions: Hyperthyroidism

Interventions: Device: Additional acquisitions with the investigational gamma-camera " MoTI ".

First Posted Date: 2024-04-17

Last Posted Date: 2024-05-08

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 20

Registration Number: NCT06371339

Locations: 🇫🇷
IUCT-O, Toulouse, France

Study of Biologic Tumor and Plasma Biomarkers of Response to TTFields in Patients Treated for Newly Diagnosed Glioblastoma

Not Applicable

Recruiting

Conditions: Glioblastoma

First Posted Date: 2024-01-24

Last Posted Date: 2024-08-29

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 80

Registration Number: NCT06222138

Locations: 🇫🇷
IUCT-O, Toulouse, France

Male breAsT cAncer preDisposition Factor

Recruiting

Conditions: Breast Cancer

Interventions: Other: Questionnaire completion

First Posted Date: 2024-01-23

Last Posted Date: 2024-11-06

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 150

Registration Number: NCT06219187

Locations: 🇫🇷
IUCT-O, Toulouse, France

A Study to Evaluate Pre- or Post-operative HYPOfractionated Radiation Therapy in Aged (≥ 70 Years Old) or "Fragile" (≥ 65 Years) Patients With Limb or Trunk Soft Tissue SARComa.

Phase 2

Recruiting

Conditions: Soft Tissue Sarcoma

Interventions: Procedure: Patient will undergo surgery before receive the adjuvant hypofractionated radiation therapy (40 Gy in 15 fractions).
Procedure: Patients will receive the hypofractionated radiation therapy (30 Gy in 5 fractions) prior to surgery.

First Posted Date: 2023-09-01

Last Posted Date: 2024-10-29

Lead Sponsor: Institut Claudius Regaud

Target Recruit Count: 70

Registration Number: NCT06022159

Locations: 🇫🇷
Institut Bergonie, Bordeaux, France
🇫🇷
Centre Oscar Lambret, Lille, France
🇫🇷
Chu de Limoges, Limoges, France

and more 8 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy